Why the study?
The study was conducted to evaluate the noninferiority of a transdermal bisoprolol patch (TY-0201) compared with oral bisoprolol in patients with persistent or permanent atrial fibrillation.
Does bisoprolol transdermal patch reduce heart rate non-inferiorly to bisoprolol oral formulation in Japanese patients with persistent or permanent atrial fibrillation?
Does bisoprolol transdermal patch reduce heart rate non-inferiorly to bisoprolol oral formulation in Japanese patients with persistent or permanent atrial fibrillation?
Bisoprolol transdermal patch provides similar heart rate reduction to oral bisoprolol in patients with persistent or permanent atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Transdermal bisoprolol meets noninferiority for AF rate control; confirms a viable alternative to oral therapy in practice and trials.
BACKGROUND: TY-0201 (TY) is a transdermal patch containing bisoprolol. The objectives of this study were to evaluate the noninferiority of TY to bisoprolol oral formulation (BO) in patients with persistent or permanent atrial fibrillation (AF). METHODS: In this multicenter, double-blind, comparative study, Japanese patients with persistent or permanent AF were randomized to TY 4-mg (n=55), TY 8-mg (n=55), BO 2.5-mg (n=55), or BO 5-mg (n=55) groups. All patients were administered TY 4mg or BO 2.5mg once a day for the first 2 weeks. Patients in the TY 8-mg or BO 5-mg group, in whom dose escalation was required, were administered TY 8mg or BO 5mg for a further 2 weeks, and the other patients continued to receive TY 4mg or BO 2.5mg. The primary endpoint was a change in 24-h mean heart rate (mHR) from baseline by Holter electrocardiogram, and the noninferiority of the TY 4-mg to the BO 2.5-mg groups and that of the TY 8-mg to the BO 5-mg groups were evaluated. RESULTS: Adjusted means of changes in 24-h mHR from baseline in the TY 4-mg, TY 8-mg, BO 2.5-mg, and BO 5-mg groups were -12.3, -13.8, -12.7, and -14.3bpm, respectively. Differences between values for the TY 4-mg and BO 2.5-mg groups and between values for the TY 8-mg and BO 5-mg groups were estimated to be 0.5 (95% CI: -1.9 to 2.9) and 0.5 (-1.9 to 2.9)bpm, respectively, which did not exceed the predefined noninferiority margins. The incidence of adverse events did not differ between the groups. CONCLUSIONS: In Japanese patients with persistent or permanent AF, TY 4mg and TY 8mg had heart rate-reducing effects similar to those of BO 2.5mg and BO 5mg, respectively.
No takes yet. Share an insight, caveat, or question.
Yamashita et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: